Home LiteratureArticle Details
PMID: 9151895 Published · ppublish English Journal Article Research Support, Non-U.S. Gov't Research Support, U.S. Gov't, P.H.S.

Chronic tumor necrosis factor alters T cell responses by attenuating T cell receptor signaling.

The Journal of experimental medicine ·Vol. 185 ·No. 9 ·1997-05-05 ·Pages 1573-84

Cope AP, Liblau RS, Yang XD, Congia M, Laudanna C, Schreiber RD, Probert L, Kollias G, McDevitt HO

Abstract

Repeated injections of adult mice with recombinant murine TNF prolong the survival of NZB/W F1 mice, and suppress type I insulin-dependent diabetes mellitus (IDDM) in non-obese diabetic (NOD) mice. To determine whether repeated TNF injections suppress T cell function in adult mice, we studied the responses of influenza hemagglutinin-specific T cells derived from T cell receptor (HNT-TCR) transgenic mice. Treatment of adult mice with murine TNF for 3 wk suppressed a broad range of T cell responses, including proliferation and cytokine production. Furthermore, T cell responses of HNT-TCR transgenic mice also expressing the human TNF-globin transgene were markedly reduced compared to HNT-TCR single transgenic littermates, indicating that sustained p55 TNF-R signaling is sufficient to suppress T cell function in vivo. Using a model of chronic TNF exposure in vitro, we demonstrate that (a) chronic TNF effects are dose and time dependent, (b) TNF suppresses the responses of both Th1 and Th2 T helper subsets, (c) the suppressive effects of endogenous TNF produced in T cell cultures could be reversed with neutralizing monoclonal antibodies to TNF, and (d) prolonged TNF exposure attenuates T cell receptor signaling. The finding that anti-TNF treatment in vivo enhances T cell proliferative responses and cytokine production provides evidence for a novel regulatory effect of TNF on T cells in healthy laboratory mice. These effects are more pronounced in chronic inflammatory disease. In addition, our data provide a mechanism through which prolonged TNF exposure suppresses disease in animal models of autoimmunity.

MeSH Terms
Animals CD4-Positive T-Lymphocytes/cytology,immunology Calcium/physiology Immunosuppressive Agents/administration & dosage Interferon-gamma/metabolism Interleukin-10/metabolism Interleukin-2/metabolism Interleukin-4/metabolism Lymph Nodes/cytology Lymphocyte Activation Male Mice Mice, Inbred BALB C Mice, Transgenic Receptors, Antigen, T-Cell/physiology Receptors, Tumor Necrosis Factor/physiology Recombinant Proteins Signal Transduction/drug effects T-Lymphocytes/cytology Th1 Cells/immunology Th2 Cells/immunology Tumor Necrosis Factor-alpha/administration & dosage
Chemicals
Immunosuppressive Agents Interleukin-2 Receptors, Antigen, T-Cell Receptors, Tumor Necrosis Factor Recombinant Proteins Tumor Necrosis Factor-alpha Interleukin-10 Interleukin-4 Interferon-gamma Calcium
Authors & Affiliations
9 authors, click to expand affiliations / ORCID
Cope A P
Department of Microbiology and Immunology, Stanford University School of Medicine, California 94305, USA.
Liblau R S
Yang X D
Congia M
Laudanna C
Schreiber R D
Probert L
Kollias G
McDevitt H O
References (38)
38 references, click to expand
  1. Interleukin 10(IL-10) inhibits cytokine synthesis by human monocytes: an autoregulatory role of IL-10 produced by monocytes.
    J Exp Med. 1991 Nov 1;174(5):1209-20 PMID: 1940799
  2. Effect of tumor necrosis factor alpha on insulin-dependent diabetes mellitus in NOD mice. I. The early development of autoimmunity and the diabetogenic process.
    J Exp Med. 1994 Sep 1;180(3):995-1004 PMID: 8064245
  3. The pathophysiology of tumor necrosis factors.
    Annu Rev Immunol. 1992;10:411-52 PMID: 1590993
  4. Monoclonal anti-tumor necrosis factor antibody renders non-obese diabetic mice hypersensitive to irradiation and enhances insulitis development.
    Int Immunol. 1992 May;4(5):611-4 PMID: 1510787
  5. Anti-tumor necrosis factor ameliorates joint disease in murine collagen-induced arthritis.
    Proc Natl Acad Sci U S A. 1992 Oct 15;89(20):9784-8 PMID: 1409699
  6. Leukocyte extravasation into the pancreatic tissue in transgenic mice expressing interleukin 10 in the islets of Langerhans.
    J Exp Med. 1993 Jul 1;178(1):175-85 PMID: 8100268
  7. Continuous administration of anti-interleukin 10 antibodies delays onset of autoimmunity in NZB/W F1 mice.
    J Exp Med. 1994 Jan 1;179(1):305-10 PMID: 8270873
  8. Efficient presentation of soluble antigen by cultured human dendritic cells is maintained by granulocyte/macrophage colony-stimulating factor plus interleukin 4 and downregulated by tumor necrosis factor alpha.
    J Exp Med. 1994 Apr 1;179(4):1109-18 PMID: 8145033
  9. Recombinant human IL-10 prevents the onset of diabetes in the nonobese diabetic mouse.
    Clin Immunol Immunopathol. 1994 May;71(2):169-75 PMID: 8181185
  10. Randomised double-blind comparison of chimeric monoclonal antibody to tumour necrosis factor alpha (cA2) versus placebo in rheumatoid arthritis.
    Lancet. 1994 Oct 22;344(8930):1105-10 PMID: 7934491
  11. A role for non-MHC genetic polymorphism in susceptibility to spontaneous autoimmunity.
    Immunity. 1994 Apr;1(1):73-83 PMID: 7889402
  12. Treatment of Crohn's disease with anti-tumor necrosis factor chimeric monoclonal antibody (cA2).
    Gastroenterology. 1995 Jul;109(1):129-35 PMID: 7797011
  13. IRS-1-mediated inhibition of insulin receptor tyrosine kinase activity in TNF-alpha- and obesity-induced insulin resistance.
    Science. 1996 Feb 2;271(5249):665-8 PMID: 8571133
  14. Genetic susceptibility to Leishmania: IL-12 responsiveness in TH1 cell development.
    Science. 1996 Feb 16;271(5251):984-7 PMID: 8584935
  15. Intravenous injection of soluble antigen induces thymic and peripheral T-cells apoptosis.
    Proc Natl Acad Sci U S A. 1996 Apr 2;93(7):3031-6 PMID: 8610163
  16. Greatly accelerated lymphadenopathy and autoimmune disease in lpr mice lacking tumor necrosis factor receptor I.
    J Immunol. 1996 Apr 15;156(8):2661-5 PMID: 8609380
  17. Inhibition of tumor necrosis factor activity minimizes target organ damage in experimental autoimmune uveoretinitis despite quantitatively normal activated T cell traffic to the retina.
    Eur J Immunol. 1996 May;26(5):1018-25 PMID: 8647162
  18. IL-10 is necessary and sufficient for autoimmune diabetes in conjunction with NOD MHC homozygosity.
    J Exp Med. 1996 Jun 1;183(6):2663-8 PMID: 8676087
  19. Role of cytokines in rheumatoid arthritis.
    Annu Rev Immunol. 1996;14:397-440 PMID: 8717520
  20. Models of T cell anergy: is there a common molecular mechanism?
    J Exp Med. 1996 Jul 1;184(1):1-8 PMID: 8691122
  21. Interleukin-10 induces a long-term antigen-specific anergic state in human CD4+ T cells.
    J Exp Med. 1996 Jul 1;184(1):19-29 PMID: 8691133
  22. Selective activation of the calcium signaling pathway by altered peptide ligands.
    J Exp Med. 1996 Oct 1;184(4):1525-30 PMID: 8879224
  23. Local expression of transgene encoded TNF alpha in islets prevents autoimmune diabetes in nonobese diabetic (NOD) mice by preventing the development of auto-reactive islet-specific T cells.
    J Exp Med. 1996 Nov 1;184(5):1963-74 PMID: 8920883
  24. Heterogeneity among T cells in intracellular free calcium responses after mitogen stimulation with PHA or anti-CD3. Simultaneous use of indo-1 and immunofluorescence with flow cytometry.
    J Immunol. 1986 Aug 1;137(3):952-61 PMID: 2424993
  25. Tumour necrosis factor alpha stimulates resorption and inhibits synthesis of proteoglycan in cartilage.
    Nature. 1986 Aug 7-13;322(6079):547-9 PMID: 3736671
  26. Immunoregulatory activity of recombinant human tumor necrosis factor (TNF)-alpha: induction of TNF receptors on human T cells and TNF-alpha-mediated enhancement of T cell responses.
    J Immunol. 1987 Mar 15;138(6):1786-90 PMID: 3029221
  27. Tumour necrosis factor-alpha in murine autoimmune 'lupus' nephritis.
    Nature. 1988 Jan 28;331(6154):356-8 PMID: 2893286
  28. Tumor necrosis factor mediates myelin and oligodendrocyte damage in vitro.
    Ann Neurol. 1988 Apr;23(4):339-46 PMID: 3132891
  29. IFN-gamma and tumor necrosis factor-alpha. Cytotoxicity to murine islets of Langerhans.
    J Immunol. 1988 Oct 1;141(7):2325-9 PMID: 3139756
  30. Generation and characterization of hamster monoclonal antibodies that neutralize murine tumor necrosis factors.
    J Immunol. 1989 Jun 1;142(11):3884-93 PMID: 2469726
  31. Potential antiinflammatory effects of interleukin 4: suppression of human monocyte tumor necrosis factor alpha, interleukin 1, and prostaglandin E2.
    Proc Natl Acad Sci U S A. 1989 May;86(10):3803-7 PMID: 2786204
  32. Chronic therapy with recombinant tumor necrosis factor-alpha in autoimmune NZB/NZW F1 mice.
    Clin Immunol Immunopathol. 1989 Sep;52(3):421-34 PMID: 2758698
  33. Prevention of diabetes in nonobese diabetic mice by tumor necrosis factor (TNF): similarities between TNF-alpha and interleukin 1.
    Proc Natl Acad Sci U S A. 1990 Feb;87(3):968-72 PMID: 2405400
  34. An intracellular calcium increase and protein kinase C activation fail to initiate T cell proliferation in the absence of a costimulatory signal.
    J Immunol. 1990 May 15;144(10):3701-9 PMID: 1970590
  35. An antibody to lymphotoxin and tumor necrosis factor prevents transfer of experimental allergic encephalomyelitis.
    J Exp Med. 1990 Oct 1;172(4):1193-200 PMID: 2212948
  36. The two different receptors for tumor necrosis factor mediate distinct cellular responses.
    Proc Natl Acad Sci U S A. 1991 Oct 15;88(20):9292-6 PMID: 1718003
  37. Chronic exposure to tumor necrosis factor (TNF) in vitro impairs the activation of T cells through the T cell receptor/CD3 complex; reversal in vivo by anti-TNF antibodies in patients with rheumatoid arthritis.
    J Clin Invest. 1994 Aug;94(2):749-60 PMID: 8040330
  38. Transgenic mice expressing human tumour necrosis factor: a predictive genetic model of arthritis.
    EMBO J. 1991 Dec;10(13):4025-31 PMID: 1721867
Article Info
Journal
The Journal of experimental medicine
Abbr.
J Exp Med
ISSN
0022-1007
Published
1997-05-05
Pages
1573-84
Language
English
Region
United States
NLM ID
2985109R
PMCID
PMC2196294
Subset
IM
Analysis Services
Analysis Services

Contact

No. 2 Wenbo Road, Zhangqiu District, Jinan, Shandong

Qilu Normal University · Genelibs Bioinformatics Lab

750 Shunhua Rd, Jinan

2F, Bldg F, University Science Park

Tel: 0531-88819269

WeChat Official Account

Follow our WeChat subscription account for real-time updates and the latest in medical and biological research.


Business Email

E-mail: [email protected]